The Annals
home help contact us subscription past issues search current issue
 QUICK SEARCH:   [advanced]


     


Drug Intelligence & Clinical Pharmacy: Vol. 19, No. 10, pp. 742-744.
© 1985 Harvey Whitney Books Company.
This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bond, W.
Right arrow Articles by Swift, B
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bond, W.
Right arrow Articles by Swift, B


Research Articles

Severe withdrawal syndrome after substitution of a short-acting benzodiazepine for a long-acting benzodiazepine

WS Bond, NJ Berwish, and B Swift

A severe withdrawal syndrome occurred in a patient after oxazepam 10 mg bid was substituted for diazepam 5 mg bid. The onset of symptoms was consistent with the rate of decline of diazepam and its active metabolite, desmethyldiazepam. Reintroduction of diazepam produced prompt symptom remission. This report and others suggest the need for caution when substituting a short-acting drug for a long-acting one, even when usual doses of each are used. The chronic use of benzodiazepines for eight months or longer prior to substitution or withdrawal appears to place the patient at a higher risk of incurring withdrawal phenomena. Slow and careful tapering of drug is required in such patients to reduce the risk of withdrawal symptoms.





homecopy help contact us subscription past issues search current issue
Copyright © 1985 by Harvey Whitney Books Company.